

October 22, 2015



## Pieris Announces Presentations at Upcoming R&D Conferences

BOSTON, MA -- (Marketwired) -- 10/22/15 --

**Pieris Pharmaceuticals, Inc.** (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary [Anticalin](#)<sup>®</sup> technology platform, announced today presentations at three R&D conferences in the month of November: The Society for Immunotherapy of Cancer (SITC), The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and The PEGS Europe Summit.

The details for each presentation are as follows:

- **Protein Engineering Summit Europe (PEGS)**, Lisbon, Portugal, November 2 - 6, 2015 at the EPIC SANA Lisboa Hotel
  - *Presentation Time:* Wednesday, November 4, 2015 at 4:15 pm in the Bispecifics and Novel Biotherapeutics track in the session "Bispecifics for Immuno-oncology"
  - *Presentation:* A Podium Presentation entitled "Bispecific Anticalin fusion proteins for localized targeting of immune cells for application in immuno-oncology"
- **Society for Immunotherapy of Cancer (SITC)**, 30<sup>th</sup> Anniversary Annual Meeting in National Harbor, MD, November 4 - 8, 2015, at the Gaylord National Hotel & Convention Center
  - *Poster Session:* November 6, 2015 from 6:15 pm to 7:30 pm and November 7, 2015 from 12:30 pm to 2:00 pm
  - *Presentation:* A poster presentation entitled "Costimulatory T-cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein" (Poster Number: 198)
- **AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics**, Boston, MA, November 5 - 9, 2015 at the Hynes Convention Center
  - *Poster Session:* Sunday, November 8, 2015 from 12:30 pm to 3:30 pm, Poster Session C, Immune Modulators, Hall C-D
  - *Presentation:* A poster presentation entitled "Costimulatory T-cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein" (Abstract # C205)

Stephen Yoder, Pieris President and CEO, commented, "As we continue to advance our pipeline of immuno-oncology multispecifics, we're pleased to present a diverse set of emerging preclinical data at a number of prestigious conferences. The data will showcase the power of our Anticalin platform for the development of novel tumor-targeted immunotherapies with the potential for enhanced efficacy and safety."

### ***About Pieris Pharmaceuticals:***

Pieris is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat severe asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin<sup>®</sup>, Anticalins<sup>®</sup> are registered trademarks of Pieris. For more information visit [www.pieris.com](http://www.pieris.com).

### ***Forward Looking Statements***

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; our liquidity and ability to fund our future operations; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at [www.sec.gov](http://www.sec.gov), including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and the Company's Quarterly Reports on Form 10-Q.

#### **Company Contact:**

Pieris Pharmaceuticals, Inc.  
Darlene Deptula-Hicks  
SVP & Chief Financial Officer  
+1-603-553-5803  
[deptula@pieris.com](mailto:deptula@pieris.com)

#### **Investor Relations Contact:**

The Trout Group  
Thomas Hoffmann  
+1-646-378-2931  
[thoffmann@troutgroup.com](mailto:thoffmann@troutgroup.com)

or

The Del Mar Consulting Group, Inc.

Robert Prag  
President  
+1-858-794-5000  
[bprag@delmarconsulting.com](mailto:bprag@delmarconsulting.com)

Media Inquiries:  
Gretchen Schweitzer  
+49 172 861 8540  
[gschweitzer@macbiocom.com](mailto:gschweitzer@macbiocom.com)

Source: Pieris Pharmaceuticals, Inc.